3M Drug Delivery Systems is marking the 25th anniversary of the launch of the Aerolin Autohaler breath-activated salbutamol (albuterol) MDI. According to the company, over 120 million units of the Autohaler device have been manufactured since the inhaler was developed at 3M’s Loughborough, UK facility.
3M DDS Global Respiratory Laboratory Manager Richard Moody commented, “The Autohaler device met a need because it ensures the patient receives the full dose at the correct point in the inhalation cycle, helping compliance and improving drug delivery to the lung.”
The company also said that development of breath-actuated devices for the treatment of COPD is “a key area for future development.”
Earlier this year, 3M announced that it would expand the Loughborough MDI facility.
